Ingrid H. Robertson

Ingrid H. Robertson

Auto-generated profile, based on publicly available information

Ingrid H. Robertson

Department of Chemistry, University of Washington, Seattle, Washington 98195, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
AHA. J. Haack
A. J. Haack
LBL. G. Brown
L. G. Brown
YZY. Zeng
Y. Zeng
TKtaushif khan
taushif khan
IRI. H. Robertson
I. H. Robertson
ATA. B. Theberge
A. B. Theberge
Transcriptomic responses to wildfire smoke are difficult to study given the unpredictability of wildfires and the challenges of collecting blood during active disasters. To overcome these challenges, we developed a flexible study design leveraging homeRNA, our at-home blood collection and RNA stabilization kit. Between June 2021 and April 2022, 58 participants across 10 U.S. states collected 635 blood samples before, during, and after wildfire events. This responsive approach captured three exposure groups: high exposure in Okanogan County, Washington, medium exposure from transported smoke, and low exposure. During the 10-month study, 93% of participants (n=54/58) returned at least 6 samples. In a preliminary exploratory analysis, we analyzed 770 genes with a Nanostring panel from nine participants (6 high, 3 low-medium exposure) using the BloodGen3 framework. In the high exposure participants, we observed trends toward overexpression of inflammation (inflammation aggregates A33 and A35, and modules M13.1 and M13.12), with concurrent underexpression of adaptive immune responses (lymphocytic aggregates A1 and A6, B cell module M13.18, T cell modules M16.24 and M15.38). This study establishes that homeRNA enables flexible, responsive sampling during disasters, overcoming traditional logistical barriers to capture time-sensitive biological data across dispersed populations.

27 February 2025 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
WTWan‐Chen Tu
Wan‐Chen Tu
IRIngrid H. Robertson
Ingrid H. Robertson
ABAndrea Blom
Andrea Blom
EAElena Alfaro
Elena Alfaro
VSVictoria A. M. Shinkawa
Victoria A. M. Shinkawa
ATAshleigh B. Theberge
Ashleigh B. Theberge
State the Purpose: Obtaining high‐quality samples to diagnose streptococcal pharyngitis in pediatric patients is challenging due to discomfort associated with traditional pharyngeal swabs. This may cause reluctance to go to the clinic, inaccurate diagnosis, or inappropriate treatment for children with sore throats. Here, we determined the efficacy of CandyCollect, a lollipop‐inspired open‐microfluidic pathogen collection device, to capture Group A Streptococcus (GAS) and compare user preference for CandyCollect, conventional pharyngeal swabs, or mouth swabs in children with pharyngitis and their caregivers.Results: All child participants (30/30) were positive for GAS by qPCR on both the mouth swab and CandyCollect. Caregivers ranked CandyCollect as a good sampling method overall (27/30), and all caregivers (30/30) would recommend CandyCollect for children 5 years and older. Twenty‐three of 30 children “really like” the taste and 24/30 would prefer to use CandyCollect if a future test were needed. All caregivers (30/30) and most children (28/30) would be willing to use CandyCollect at home.Conclusion: All participants tested positive for GAS on all three collection methods (pharyngeal swab, mouth swab, and CandyCollect). While both caregivers and children like CandyCollect, some caregivers would prefer a shorter collection time. Future work includes additional studies with larger cohorts presenting with pharyngitis of unknown etiology and shortening collection time while maintaining the attractive form of the device.

16 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
JSJ. Carlos Sanchez
J. Carlos Sanchez
IRIngrid H. Robertson
Ingrid H. Robertson
VSVictoria A. M. Shinkawa
Victoria A. M. Shinkawa
XSXiaojing Su
Xiaojing Su
WTWan-Chen Tu
Wan-Chen Tu
ATAshleigh B. Theberge
Ashleigh B. Theberge
The CandyCollect device is a lollipop-inspired open fluidic oral sampling device designed to provide a comfortable user sampling experience. We demonstrate that the CandyCollect device can be coupled with a rapid antigen detection test (RADT) kit designed for Group A Streptococcus (GAS). Through in vitro experiments with pooled saliva spiked with Streptococcus pyogenes we tested various reagents and elution volumes to optimize the RADT readout from CandyCollect device samples. The resulting optimized protocol uses the kit-provided reagents and lateral flow assay (LFA) while replacing the kit’s pharyngeal swab with the CandyCollect device, reducing the elution solution volume, and substituting the tube used for elution to accommodate the CandyCollect device. Positive test results were detected by eye with bacterial concentrations as low as the manufacturer’s “minimal detection limit” - 1.5×10 5 CFU/mL. LFA strips were also scanned and quantified with image analysis software to determine the signal-to-baseline ratio (SBR) and categorize positive test results without human bias. We tested our optimized protocol for integrating CandyCollect and RADT using CandyCollect clinical samples from pediatric patients (n=6) who were previously diagnosed with GAS pharyngitis via pharyngeal swabs tested with RADT as part of their clinical care. The LFA results of these CandyCollect devices and interspersed negative controls were determined by independent observers, with positive results obtained in four of the six participants on at least one LFA replicate. Taken together, our results show that CandyCollect devices from children with GAS pharyngitis can be tested using LFA rapid tests. Table of Contents/Abstract Figure:

6 February 2026 in medRxiv
Verified
Preprint
Open access
FSFilip Stefanovic
Filip Stefanovic
IRIngrid Robertson
Ingrid Robertson
KMKathleen Moloney
Kathleen Moloney
JEJane Edelson
Jane Edelson
SNSerena Nguyen
Serena Nguyen
ATAshleigh B Theberge
Ashleigh B Theberge
Structured Abstract Importance: Remote sampling technologies are invaluable for protecting both participants and researchers when studying highly infectious diseases. When leveraged for longitudinal studies, remote sampling with transcriptomic readouts is a powerful tool for studying the host immune response. Additionally, remote study flexibility circumvents common barriers to research participation including length of commute, transportation, and scheduling, thereby expanding access to clinical research. Objective: In this work, we investigate the effectiveness of a remote study model for reaching women from underrepresented, underserved, and underreported (U3) populations. We sought to recruit individuals who qualify as underrepresented in clinical research, who are located in rural areas, or who come from disadvantaged backgrounds per the NIH definition. Design: In this longitudinal study, U3 women positive for COVID-19 were enrolled and followed over the course of 6 months. In the first month of the infection, participants (n = 40) self-collected a set of 5 nasal swabs, 5 homeRNA-stabilized blood samples, and 2 additional unstabilized blood samples at first and last sampling. Sampling time points were spaced 5 days apart, so that the total of the 5 time points was completed within 25 days. homeRNA is a platform for remote self-collection of blood samples with subsequent RNA stabilization. A subset of participants likely to develop post-acute sequelae of COVID-19 (PASC) and their age-matched controls were selected to self-collect an additional set of 5 nasal swabs and 5 homeRNA-stabilized blood samples during month 3 of study participation, with the same sampling frequency. All participants were resurveyed at months 4, 5, and 6 about their symptoms. Participants also completed surveys at each sampling and a more comprehensive survey about study experience after each set of 5 time points. Setting: This was a fully remote study with all sampling supplies and instructions shipped to the participants. Participants self-collected blood and nasal swabs at home and shipped these back to our lab for further processing. Surveys were administered electronically using REDCap. Participants: For this study, we enrolled women who were 18 or older, met the NIH criteria for U3, and who had tested positive for SARS-CoV-2 within a week of enrollment. Further, we excluded protected populations including individuals who were pregnant and/or incarcerated. Of the 334 individuals who completed the screening process, 65 were invited into the study based on the eligibility criteria and balancing age, race/ethnicity, and state of residence to closely correspond to the demographics of the United States. Of the 65 invited individuals, 40 were fully enrolled in the study and 39 completed all study components. Main Outcomes and Measures: Prior to the study, we proposed that the increased flexibility of a remote study design would allow for participation of populations underrepresented in clinical research. The primary measurements planned for this study consisted of usability data and general experience in a longitudinal study. These data were collected by self report using electronically administered surveys. The Consolidated Framework for Implementation Research (CFIR), a well-established implementation science framework, was used to guide the development of questions about usability and study experience. Results: 40 women were recruited from 19 states, with diverse racial backgrounds (62% White, 15% Black or African American, 10% Asian, 5% American Indian or Alaska Native, 5% Other, 3% More than one race), a mostly even age distribution (26% ages 20 - 29, 15% ages 30 - 39, 31% ages 40 - 49, 28% ages 50+), and most of whom (80%) are categorized as having a disadvantaged background per the NIH. Survey responses show high satisfaction with the study, where all participants who completed the study (100%, n = 39/39) indicating that they would be willing to participate in a similar study again, with most (n = 32/39) indicating a willingness to participate for up to 4 years with around 15 samples collected per year. We note that 4 years was the longest time period that participants were able to select in their surveys, suggesting that participants may be willing to participate for even longer periods. Most (>90%) either agreed or strongly agreed that all components of the kit were easy to use. Conclusions and Relevance: The high retention (98%, n = 39/40) and satisfaction of participants in this study indicates the utility of a remote study design for longitudinal research. We also find that study topic, flexibility of study, and positive interactions with the study team are important factors for participant recruitment and retention. This work suggests that the increased flexibility of a fully remote design enables engagement of individuals who may otherwise be excluded from clinical research.

19 August 2025 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
KLKelsey May Leong
Kelsey May Leong
JSJuan Carlos Sanchez
Juan Carlos Sanchez
CCCosette Craig
Cosette Craig
JTJohn A. Tatka
John A. Tatka
RARené R. Arvizu
René R. Arvizu
AOAyokunle Olanrewaju
Ayokunle Olanrewaju
The O2C securely seals the open microchannels of the CandyCollect device to create a continuous closed channel for seamless delivery of elution reagents to release antigens at the press of a button for subsequent lateral flow detection.

6 November 2026 in bioRxiv
Verified
Preprint
Open access
MEMadeleine Eakman
Madeleine Eakman
IRIngrid H. Robertson
Ingrid H. Robertson
XWXiaofu Wei
Xiaofu Wei
FSFilip Stefanovic
Filip Stefanovic
TCTj Caira
Tj Caira
ATAshleigh B Theberge
Ashleigh B Theberge
In-person research can introduce barriers to participation, including proximity to a study site and scheduling constraints. Our lab developed the homeRNA platform to address these barriers, enabling remote blood collection and RNA stabilization for transcriptomic research. To increase the applicability of homeRNA for large-scale studies, a redesigned version was developed with modifications to 1) improve usability for both participants and downstream processing laboratories, 2) allow for high-throughput manufacturing, and 3) extend the shelf life of the stabilizer tube. In this work, we systematically tested this design against anticipated stresses that can occur throughout a remote study (e.g., high temperature exposure during shipment) to identify and characterize its limitations. We found that the homeRNA device can be prepared and stored at room temperature at least three months in advance of sampling with continued shelf life analysis underway. We also found that the homeRNA platform produces RNA of sufficient quality for downstream transcriptomic analysis under standard shipping durations (i.e., 2 days in transit) and ambient-to-high temperature conditions (i.e., 25-40 °C) and that RNA quality is unaffected by variable blood volumes collected by participants (mean RIN=7.8 in blood volumes 0.25-1 mL). Lastly, we also found that samples can be stored in typical cold storage temperatures and even up to standard room temperature for at least 4 weeks (mean RIN=8.1 after 4 weeks of storage at -80 to 20 °C). This work validates that the new homeRNA platform is robust to many of the expected stresses that samples can experience during remote studies.